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Human immunodeficiency virus (HIV)-1 depends on
the host cell machinery to support its replication.
To discover cellular factors associated with HIV-1
replication, we conducted a genome-scale siRNA
screen, revealing more than 311 host factors, includ-
ing 267 that were not previously linked to HIV. Sur-
prisingly, there was little overlap between these
genes and the HIV dependency factors described re-
cently. However, an analysis of the genes identified in
both screens revealed overlaps in several of the asso-
ciated pathways or protein complexes, including the
SP1/mediator complex and theNF-kB signaling path-
way. cDNAs for a subset of the identified genes were
used to rescue HIV replication following knockdown
of the cellular mRNA providing strong evidence that
the following six genes are previously uncharacter-
ized host factors for HIV: AKT1, PRKAA1, CD97,
NEIL3, BMP2K, and SERPINB6. This study highlights
both the power and shortcomings of large scale
loss-of-function screens in discovering host-patho-
gen interactions.
INTRODUCTION
HIV-1/AIDS continues to be a global health threat despite
the recent introductions of novel therapeutics. Most currently
approved HIV therapeutics target viral enzymes, including
reverse transcriptase, protease, and integrase (Cohen et al.,
2008). Despite the effectiveness of antiviral regimens, drug resis-
tance can emerge due to the low fidelity of HIV reverse transcrip-
tase (Clavel and Hance, 2004). Antiviral medicines targeting host
factors required for HIV infection or replication that do not require
contact with viral gene products for efficacymay provide a higher
barrier to the development of resistance (Flexner, 2007).
The HIV-1 genome is approximately 9.8 kb in length and
encodes only 15 proteins, thus HIV must exploit host-encoded
proteins to complete each step of its life cycle, including entry
into the host cell, uncoating, reverse transcription, nuclearCell Hostimport, integration, transcription, translation, viral assembly,
and budding. The identity of these host factors remains incom-
pletely understood (Goff, 2007; Lama and Planelles, 2007).
Therefore, unbiased, genome-scale experiments designed to
identify host factors associated with viral replication will offer
the potential to further understand HIV-host interactions and
identify host targets for developing anti-HIV therapeutics.
RNA interference (RNAi) is a biological phenomenon in which
small double-stranded RNA (dsRNA) molecules present in the
cytoplasm of a cell lead to the destruction of cognate mRNAs
(Elbashir et al., 2001). This mechanism can be exploited by trans-
fecting siRNAs designed to target specific genes into a cell and
evaluating the effect of knocking down the expression of these
genes on a cellular process (Dorsett and Tuschl, 2004; Moffat
and Sabatini, 2006). To identify host factors associated with
HIV infection, we conducted a genome-scale siRNA screen in
which cells transfected with siRNAs were infected with HIV
and evaluated for viral replication at two time points following
infection. Three-hundred and eleven host factors were identified
in the screen, including two-hundred and sixty genes that have
not been previously described as interacting with HIV. An analy-
sis of the genes targeted by the effective siRNAs from the screen
revealed little overlap between the specific HIV dependency
factors described in a recently published study (Brass et al.,
2008). Although most of the factors identified in the two studies
were distinct, several were found to be associated within the
same protein complexes or canonical pathways, including the
SP1/mediator complex and the NF-kB signaling pathway. These
data have therefore not only revealed unique proteins warranting
further study but have also shown the potential power of combin-
ing the analysis of the highly complex data sets that is derived
from these large-scale siRNA screens.
RESULTS
We carried out a siRNA screen in HeLa P4/R5 cells, which
contain ectopically expressed CD4 as well as an integrated
HIV LTR-driven b-gal reporter (Kimpton and Emerman, 1992).
These cells were transfected with siRNAs in duplicate 384-well
plates. Twenty-four hours following transfection, the cells were
infected with HXB2 HIV-1. b-gal activity was measured as a sur-
rogate for viral infection either 48 hr following infection, to identify& Microbe 4, 495–504, November 13, 2008 ª2008 Elsevier Inc. 495
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transcription of the HIV LTR—or 96 hr later, to identify factors as-
sociated with all stages of infection from virus entry to release
and spread (Figure 1A). The screen was optimized using siRNAs
targeting cyclin T1 and Tsg101, factors associated with HIV
Tat-mediated transcription and HIV particle release, respectively
(Bieniasz et al., 1999; Garrus et al., 2001).Multiple siRNAs target-
ing cyclin T1 significantly inhibited HIV replication comparedwith
a negative control siRNA at both 48 and 96 hr postinfection (Fig-
ure 1C). siRNA targeting Tsg101 decreased HIV replication at
96 hr but not 48 hr postinfection, which is consistent with its role
as a budding factor for HIV particle release (Garrus et al., 2001).
Genome-Scale siRNA Screen Hits
Using this platform, we screened a siRNA library targeting 19,709
genes with 22,329 pools of 3 siRNAs per gene. siRNA pools were
classified as hits by comparing the b-gal activity of each well to
the positive and negative controls on the corresponding plate
as described (Zhang et al., 2006, 2007; Zhang, 2007a, 2007b).
siRNAs that decreased b-gal activity by two strictly standardized
mean differences (SSMD) relative to the corresponding negative
control wells at both 48 and 96 hr postinfection, those that de-
creased b-gal activity at 96 hr but not at 48 hr, and those that
increased b-gal activity by at least 2-fold relative to negative con-
trols were chosen for further evaluation, allowing us the opportu-
nity to identify host factors thatmay be associatedwith both early
and late events in viral replication, as well as potentially identify-
ing restriction factors. We also monitored cell viability to rule out
general toxicity by eliminating hits that decreased cell viability by
greater than two standarddeviations.One thousand twohundred
and seventy-six pools were identified by these criteria (5.7%)
(Figure 1F). These pools were then rescreened in triplicate and
931 pools were confirmed (73%). To further validate these hits,
a staged assay was carried out in which a virus shed from
siRNA-treated, HIV-infected HeLa P4/R5 cells was used to infect
fresh HeLa P4/R5 cells (Figure 1B). b-gal activity in the freshly
infected cells was measured 48 hr later to determine siRNA ef-
fects on producing infectious HIV particles from primary infected
cells (Figure 1D). siRNAs targeting 390 genes were confirmed by
this additional assay. These 390 geneswere considered to be the
primary screen hits (Figure 1F, Table S1). The 390 primary screen
hits were then screened in silico against a database containing
information on expression of over 11,700 genes in multiple tis-
sues, including activated T cells and macrophage (Castle et al.,
2008). Three hundred and eleven of the primary screen hits were
shown to be expressed in activated T cells or macrophage, the
two predominant cellular targets of HIV (Table S2). Two hundred
and ninety-one of these siRNAs were selected for further valida-
tion using independent siRNAs. The independent siRNAs target-
ing 232 of the identified genes affected HIV infection (Figure 1F,
Table S1). These 232 genes were considered to be confirmed
hits. Of the 232 confirmed hits, 205 of the siRNAs inhibited HIV
infection, siRNAs targeting one gene (GM2A, GM2 ganglioside
activator) enhanced HIV replication approximately 2-fold, and
siRNAs targeting 26 of the genes had either activating or inhibit-
ing activities, possibly suggesting tight cellular regulation of
mRNA levels for these genes.
To gain more insight into the mechanisms of these factors in
HIV infection, we determined which siRNAs were likely to target496 Cell Host & Microbe 4, 495–504, November 13, 2008 ª2008 Elsgenes associated with HIV Tat-mediated transactivation of the
viral LTR promoter. HeLa P4/R5 cells were first transfected
with siRNAs targeting genes identified in the primary siRNA
screen, followed by transfection with a plasmid driving expres-
sion of HIV-Tat. b-gal activity was then measured as above.
siRNAs targeting cyclin T1 inhibited Tat-mediated LTR-b-gal
expression, thus validating the assay (Figure 1D). We found
that siRNAs targeting 81 of the 232 confirmed hits inhibited
Tat-driven expression of b-gal by at least 40% (Table S1).
Pathway Analysis of siRNA Hits
Among the 311 host factors (232 confirmed) we identified in our
screen, 44 were previously linked to HIV infection when com-
pared with both the NIAID HIV, Human Protein Interaction Data-
base, andwith the recently published results of a separate siRNA
screen for host factors associated with HIV replication (Brass
et al., 2008) (Figure 2A). The genes identified with the most
well-characterized interactions with HIV replication include pri-
marily those involved with viral entry, Tat-mediated transcription
of the HIV LTR, and Rev. Entry factors include the well-charac-
terized viral coreceptors, CD4, and CXCR4. Genes identified in
the screen with prior links to Tat-mediated transcription through
the HIV LTR include GTF2A1, GTF2H1, members of the SP-1/
mediator complex (MED4, MED7, and MED28), components of
the NF-kB transcription pathway (NF-kB1, REL A, AKT, IL-1A,
andMAP3K14), and components of the DNA-directed RNApoly-
merase II complex (POLR2H, POLR2K, and POLR2L). Largely
consistent with published data, siRNA targeting all of these
genes but GTF2H1 disrupted Tat-driven expression of b-gal in
the assay described above (Table S1). Finally, two genes associ-
ated with Rev-dependent export of HIV RNA,DDX3X, and XPO1,
were also targets of effective siRNAs from the screen.
When the results of our siRNA screen were compared to that
recently published by Brass et al. (2008), we found an overlap
of only 15 genes. Brass et al. (2008) identified 284 genes out of
21,121 pools screened, while we identified 232 genes out of
19,709 genes screened. If the same number of genes were ran-
domly selected from each screening population, the overlap
would be expected to be (284/21,121) 3 (232/19,709) 3
20,000, or approximately three genes. Thus, the overlap be-
tween the two genome-scale siRNA screens for HIV cofactors
is greater than the amount of overlap that would be expected
by chance. Having been identified by two distinct siRNA screens
with different strains of HIV, different measurements of efficacy
and using siRNAs designed via distinct algorithms, these genes
are likely to encode essential factors in HIV replication. Seven out
of the fifteen genes are also found in the NIAID database and in-
clude CD4, CXCR4, DDX3D, TCEB3, JAK1, AKT1, and REL A.
The data for these and the other overlapping genes identified
in both screens are shown (Figure 2B). Of the eight effective
siRNA targets that overlapped in only the two genome-scale
screens, seven showed similar levels of inhibition of viral replica-
tion at both 48 and 96 hr postinfection in our assay, suggesting
these host factors are associated with the portion of the HIV
life cycle up to and including Tat-mediated transcription of the
HIV LTR. The other siRNA pool, which targeted RNF28, was
more effective at 96 hr postinfection than at 48 hr, suggesting ei-
ther that RNF28 is involved in later stages of the viral life cycle, or
that it has a relatively long half-life such that the impact ofevier Inc.
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RNAi Screen for HIV Host FactorsFigure 1. High-Throughput siRNA Screen for HIV Host Factors
(A) Schematic representation of the screen. siRNA pools were transfected into HeLa P4/R5 cells in a 384-well format. After 24 hr, HIV-1 HXB2 virus was added,
and 48 hr or 96 hr postinfection b-gal substrate was added and relative light units (RLU) measured.
(B) Schematic representation of the staged assay. siRNA pools were transfected into HeLa P4/R5 cells. After 24 hr, HIV-1 HXB2 virus was added, and 48 hr later the
cultured supernatantwas removed and added to freshHeLaP4/R5 cells. After an additional 48 hr, b-gal substratewas addedand relative light units (RLU)measured.
(C) siRNAs against cyclin T1 or Tsg101 inhibit HIV infection. The indicated siRNAs were transfected into HeLa P4/R5 cells as described above and their effects on
HIV replication were quantified relative to negative control luciferase siRNA (Luc). siRNAs targeting cyclin T1 or Tsg101 inhibit HIV infection in the staged assay
(right). Error bars indicate the standard deviation of three experiments.
(D) siRNAs against cyclin T1 or Tsg101 inhibit HIV infection in the staged assay. The indicated siRNAswere transfected into HeLa P4/R5 cells as described above
and their effects on HIV replication were quantified relative to negative control luciferase siRNA (Luc). siRNAs targeting cyclin T1 or Tsg101 inhibited HIV infection
in the staged assay. Error bars indicate the standard deviation of three experiments.
(E) Tat transactivation assay. The indicated siRNAs were transfected into HeLa P4/R5 cells. After 24 hr, a mammalian expression vector of Tat was transfected
into cells. After an additional 48 hr, b-gal substrate was added and relative light units (RLU) measured. Tat-induced LTR activation was quantified relative to
control luciferase siRNA (% of Luc siRNA). siRNAs targeting cyclin T1 inhibited Tat-induced LTR activation. Error bars indicate the standard deviation of three
experiments.
(F) The flow of various filters used in the genome-scale siRNA screen. The number of hits remaining after each filter imposed is indicated in bold.Cell Host & Microbe 4, 495–504, November 13, 2008 ª2008 Elsevier Inc. 497
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72 hr following siRNA transfection.
Further analysis of the screening data revealed a number of
genes associated with previously described pathways or protein
complexes associated with HIV replication, as well as pathways
that hadnot previously been linkedwithHIV (Table 1; Supplemental
Data). In addition to three components of the SP1/mediator com-
plex previously identified as HIV dependency factors by Brass
et al. (2008) (MED4, MED7, MED28), we discovered several addi-
tional mediator components including MED6, MED8, MED11,
MED17, MED19, MED20, MED26, MED27, and MED31 (Table 1).
Notably, siRNAs targeting these mediator components also in-
hibitedHIVLTR-b-galactivation in theTat transactivationassay (Ta-
bles 1 and S1), providing further evidence that these factors are
required for Tat-dependent gene expression through the HIV LTR.
To identify pathways, confirmed siRNA hits were evaluated
using either the Ingenuity database or the GeneGo and Kegg
Figure 2. Venn Diagram of the Genome-
wide Screen Results and NIAID HIV Protein
Interaction Database
(A) Venn diagram of the current genome-wide
screen results, the Brass et al. (2008) screen re-
sults, and NIAID HIV protein interaction database.
(B) Effects of siRNA hits identified in this work and
in Brass et al. (2008) on HIV replication. Error bars
indicated the standard deviation of triplicate
siRNA transfections carried out in the confirma-
tions screen.
Databases (Figure S1, Table S2). Path-
ways associated with the Srb/Mediator
complex or with NF-kB signaling, includ-
ing ‘‘Ligand-Dependent Transcription of
Retinoid-Target Genes,’’ and ‘‘Glucocor-
ticoid Receptor Signaling,’’ were highly
enriched in both data sets. Surprisingly,
both data sets also showed a high degree
of enrichment for pathways associated
with mitochondrial function (Table 1).
Knockdown of any of the NADH dehydro-
genase subunits (NDUFA10, NDUFA6,
NDUFS6, and NDUFS7) and also the
mitochondrial proteins ATP5B and
UQCRC1 inhibited HIV infection, indicat-
ing that HIV exploits the mitochondrial
respiratory chain in its replication,
perhaps through modulating oxidative
phosphorylation (Table 1). Notably, oxi-
dative stress has been previously linked
to DNA damage and T cell apoptosis
during HIV infection (Banki et al., 1998).
Akt-Associated Pathways
in HIV Replication
The serine/threonine protein kinase Akt,
also known as protein kinase B (PKB),
plays a highly conserved role in regulat-
ing glucose and cellular energy metabo-
lism. In addition, Akt plays a major role in preventing apoptosis
and promoting cell survival (Franke et al., 1997). Tat has been
reported to activate the Akt pathway to protect cells from apo-
ptosis during HIV infection (Borgatti et al., 1997), and Brass
et al. reported that depletion of Akt inhibited HIV replication via
theNF-kBpathway. Akt was also identified in our screen (Table1,
Figure 2). Pathways linked to the hits from our siRNA screen that
also contain Akt include ‘‘Glucocorticoid Receptor Signaling,’’
‘‘NK-kB Signaling,’’ ‘‘FXR/RXR Activation,’’ and the ‘‘Adipocyto-
kine Signaling Pathway’’ (Figure S1). The enrichment of the
adipocytokine signaling pathway in the genes targeted by effec-
tive siRNAs from our screen suggests that the regulation of
cellular metabolism is essential for HIV replication. Genes asso-
ciated with the adipocytokine signaling pathway that were also
identified in our siRNA screen include AKT1, RELA, NF-kB1,
JAK1, PCK, CAMKK2, ACACB, and PRKAA1. siRNA pools
targeting all of these genes potently inhibited HIV infection at498 Cell Host & Microbe 4, 495–504, November 13, 2008 ª2008 Elsevier Inc.
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(% of control) Tat Inhibition
Mediator Complex MED11 20 19 51 +
MED14 +
MED17 21 15 44 +
MED19 50 44 51 +
MED20 24 26 42 
MED26 11 7 21 +
MED27 42 26 54 +
MED28 + 3 3 14 +
MED31 60 26 49 +
MED4 + 20 9 20 +
MED6 4 3 28 +
MED7 + 7 5 15 +
MED8 55 44 49 +
Mitochondrial Function TOMM70A + 50 48 81
ATP5B 43 24 38 
UQCRC1 42 43 60 
NDUFA10 28 20 42 
NDUFA6 39 31 43 
NDUFS6 63 35 54 
NDUFS7 72 36 52 
Adipocytokine Signaling AKT1 + 15 20 55 
PRKAA1 18 23 33 +
PCK1 25 30 45 
ACACB 75 48 51 +
CAMKK2 66 35 50 +
JAK1 + 21 27 24 +
NFKB1 6 10 31 +
RELA + 32 22 43 
IKBKG +both 48 and 96 hr postinfection (Figure 3A), as well as in the
reinfection assay described above (Figure 3B).
In order to confirm the importance of AKT and PRKAA1 in HIV
infection, a cDNA rescue experiment was carried out (Lassus
et al., 2002). siRNAs targeting the 30UTR of both AKT and
PRKAA1 mRNAs decreased both the targeted mRNA as well
as HIV infection (Figure S2). These siRNAs were then cotrans-
fected along with either a cDNA expression vector, or the
same plasmid expressing either AKT or PRKAA1 cDNAs that
lack the 30UTR. For both AKT and PRKAA1 siRNAs, the inhibition
of HIV replication caused by the 30UTR-targeting siRNAs was
restored by expression of the respective cDNA but not by the
expression vector alone (Figure 3C), further validating the essen-
tial role of AKT and PRKAA1 in HIV infection.
Four Potentially Druggable Host Factors Required
for HIV Replication
One of the objectives for conducting this genome-scale screen
for host factors associated with HIV replication was to identify
targets for developing therapeutics that would allow safe and
effective inhibition of HIV replication in HIV-infected patients. WeCell Hostthus narrowed our experimental focus to include only those
genes that were considered to have druggable domains as
defined (Hopkins and Groom, 2002). This filter reduced the
number of genes to examine from 311 to 56 (Table S3). We then
selected a group of these genes to evaluate further, based on
viability of knock-out mice, if known, and availability of reagents.
We carried out a cDNA rescue experiment as described
above for the following genes: SNF1LK, DAPK2, TNK1, CD97,
CMKLR1, EDG4, PI4KA, SERPINB6, and BMP2K. We were
able to identify siRNAs targeting the 30UTR for all of these genes
that effectively knocked down gene expression along with
reducing HIV infection. Of the cDNAs tested, however, only
CD97, SERPINB6, BMP2K, and NEIL3 were able to rescue HIV
replication (Figures 4 and S3). For these genes, effectively dem-
onstrating that (1) knockdown of the targeted mRNA by multiple
siRNAs reduces HIV infection and (2) this knockdown can be
rescued by expression of the cDNA in a non-targeted form,
clearly shows that these genes do play a role in HIV replica-
tion. All of these genes are expressed in CD4+ T cells, and, while
SERPINB6 and BMP2K are expressed fairly ubiquitously, CD97
and NEIL3 show higher expression in hematopoietic cells and& Microbe 4, 495–504, November 13, 2008 ª2008 Elsevier Inc. 499
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RNAi Screen for HIV Host FactorsFigure 3. Multiple Components of the Adipocytokine Signaling Pathway Is Required for HIV Replication
(A) siRNA depletion of the indicated components of the adipocytokine signaling pathway inhibited HIV infection. Data shown are from the triplicate siRNA
transfections carried out in the confirmation screen, and the error bars indicated the standard deviation.
(B) siRNA depletion of the indicated adipocytokine signaling molecules inhibited HIV infection in the reinfection assay. Error bars indicate the standard deviation
from triplicate transfections.
(C) Depletion of AKT and PRKAA1 by siRNAs against 30UTR of the two genes inhibited HIV replication and could be rescued by AKT or PRKAA1 cDNA expression.
Error bars indicate standard deviation (N = 3).tissues (Figure 5A). Notably, these four host factors have not
previously been linked to HIV.
We examined the role of CD97, SERPINB6, BMP2K, and
NEIL3 in HIV infection in greater detail by testing the effect of
siRNA pools targeting these four genes on different stages in
the viral life cycle. None of the siRNAs affected viral entry or
Tat-mediated gene expression (Table S1 and data not
shown). We evaluated the effect of the siRNA pools on reverse
transcription and integration by isolating DNA from siRNA-
transfected, HIV-infected HeLa P4/R5 cells, and evaluating
the level of full-length reverse transcription products and prod-500 Cell Host & Microbe 4, 495–504, November 13, 2008 ª2008 Elsucts of viral integration using the qPCR conditions described
(Butler et al., 2001). We observed a decrease in vDNA for the
cells transfected with BMP2K, NEIL3, and to a lesser extent,
SERPINB6 siRNAs, but not with CD97 siRNAs, indicating a
decrease in completion of reverse transcription (Figure 5B).
Consistent with this, all three siRNA pools also led to a decrease
in the observed level of viral integration (Figure 5C). Taken
together, the data suggest that BMP2K, NEIL3, and SERPINB6
function in HIV replication at a point following entry of the
virus into the cell but prior to the completion of reverse
transcription.evier Inc.
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RNAi Screen for HIV Host FactorsFigure 4. cDNA Rescue Experiment to Confirm the Role of the Identified siRNA Target Genes in HIV Infection
Depletion of BMP2K, CD97, NEIL3, or SERPINB6 by siRNAs against 30UTR of these genes inhibited HIV replication and this inhibitory effect could be rescued by
BMP2K, CD97, NEIL3, or SERPINB6 cDNA expression. Data expressed are inhibition of HIV infection (normalized to luciferase siRNA control) for 30UTR-targeting
siRNAs cotransfected with vector alone or with the identical vector expressing the targeted cDNA. Error bars indicate standard deviation (N = 3).DISCUSSION
In summary, we used a genome-scale RNAi screen to identify
host factors involved in HIV infection. We identified a number
of genes with well-characterized roles in HIV replication, includ-
ing the HIV coreceptors, CD4 and CXCR4, components of the
NF-kB signaling pathway, and genes associated with Rev-
dependent export of HIV RNA, therefore validating the capability
of our screen to identify host factors required for HIV replication.
Furthermore, our study identified a number of genes associated
with cellular processes previously not linked to HIV infection,
including oxidative phosphorylation and adipokine signaling.
Although the identification of a number of associated genes in
this siRNA screen does not by itself link the pathway to HIV rep-
lication, it does provide avenues for future explorations. Based
on the large number of host factors identified in this genome-
wide screen as well as that of Brass et al. (2008), and the diverse
cellular activities that they are involved in, it is clear that HIV
proteins interact extensively with host factors to promote viral
replication. Although the nature of the virus/host interdepen-
dency remains undefined for the majority of the genes we
identified, the current study provides insights into the HIV-host
interaction.
One surprising aspect of the results from this siRNA screen is
the relatively low level of overlap between the genes identified in
this study when compared with those described in a recently
published genome-scale siRNA screen for HIV host-depen-
dency factors (Brass et al., 2008). The overlapping hits include
well-characterized HIV cofactors (CD4, CXCR4, DDX3X, RELA)
as well as some that are unique to these two siRNA screens.
Given the small degree of overlap between the two screens,
the host factors identified in both screens should be consideredCell Hostmore likely to be confirmed as host factors following additional
biochemical analysis. The role of the Mediator complex in
transcription at SP1 sites and the presence of SP1 sites in the
HIV-1 LTR has been established, and both our data and that of
Brass et al. (2008) indicate that the siRNAs targeting the Media-
tor complex that were effective in both siRNA screens were likely
interfering with transcription of viral genes (Takagi and Kornberg,
2006). The role of the other overlapping hits in viral replication
has not been characterized.
Technical differences in the way the two siRNA screens
were conducted and the reagents used may in part explain the
relatively small degree of overlap between the two screens. In
both screens, a HeLa cell clone modified to express HIV core-
ceptors was transfected with siRNA and then infected with
HIV. In the Brass et al.(2008) screen, cells were transfected
with siRNA and virus was added 72 hr following transfection,
while we infected the cells 24 hr following siRNA transfection.
The 48 hr difference in the timing of the viral infection following
siRNA treatment could have biased our screen more toward
identifying host factors with higher turnover or shorter protein
half-life and the Brass et al. (2008) screen toward host factors
with lower turnover or longer half-life. Both screens used meth-
odologies to identify host factors associated with both early
and late events in the viral life cycle. We infected cells at a low
MOI and used expression of the Tat-driven reporter element
48 hr post infection to identify host factors associated in events
from viral entry through Tat-mediated gene expression, and 96 hr
post infection to identify host factors that were missed at the first
time point, either because they are associated with later steps in
viral replication or because they have a longer half-life and would
not decrease the assay signal until the second round of infection.
Our reliance on the Tat-driven reporter element for hit detection& Microbe 4, 495–504, November 13, 2008 ª2008 Elsevier Inc. 501
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RNAi Screen for HIV Host FactorsFigure 5. Expression Profiles of BMP2K, CD97, NEIL3, and SERPINB6 Genes and Their Effects on HIV Life Cycle
(A) Cell and tissue expression profile of BMP2K, CD97, NEIL3, and SERPIN B6.502 Cell Host & Microbe 4, 495–504, November 13, 2008 ª2008 Elsevier Inc.
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percentage of genes associated with Tat. The Brass et al. (2008)
screen used p24 staining as an indicator of successful infection
through translation of late viral proteins, and conducted a reinfec-
tion assay similar to the one we employed as a secondary assay
to identify factors associated with viral assembly and budding,
a strategy that may have allowed identification of more factors
associated with late events in the viral life cycle. Finally, the
two screens used siRNA library designed with distinct
algorithms, which is likely to result in differences in knockdown
efficiency for some mRNA targets.
One way to integrate seemingly disparate data when compar-
ing two siRNA screens evaluating the same biological process is
to look for common pathways or components of multiprotein
complexes targeted by the hits in each screen. As mentioned
previously, both our screen and that of Brass et al. identified
numerous, and in many cases nonoverlapping, subunits of the
Sp1/Mediator complex. Both found components of the NF-kB
signaling pathway. Additionally, both screens identified a link
between mitochondrial function and HIV replication, which
requires further study to understand the underlying mechanism.
Finally, multiple signaling molecules in the adipocytokine
pathway were found to be required for HIV infection.
We elected to focus on confirming hits with druggable domains
and where knockout mice, if they existed, did not show
any evidence of liability, in order to facilitate the identification of
targets for antiviral drug discovery programs. This resulted in
our following up on the role of a number of disparate genes in-
cluding AKT, PRKAA1, SERPINB6, BMP2K, CD97, and NEIL3.
AKT and PRKAA1 play a highly conserved role in the regulation
of cellular energy metabolism, including glucose transport, gly-
colysis, fatty acid synthesis, and protein synthesis (Whiteman
et al., 2002; Rutter et al., 2003). Investigating the link between
these biological activities and HIV replication will provide insight
into the interaction between of cellular metabolism and HIV infec-
tion. It should also be noted that both AKT and AMPK protect
cells from apoptosis induced by a variety of stimuli, so they
may act to enhance HIV replication through promoting survival
of infected cells (Borgatti et al., 1997; Bla´zquez et al., 2001).
This is consistent with the enrichment of factors associated
with cell death/apoptosis, including SERPINB6, which protects
cells from protease-mediated cell injury and death by inhibiting
the activation of serine proteases (Benarafa and Remold-
O’Donnell, 2005). NEIL3 is a hematopoietic cell-specific DNA
glycosylase/AP lyase that participates in base-excision repair
and appears to be required for an event in the viral life cycle up
to or including viral integration. This observation supports a role
for DNA repair pathways in HIV infection (Yoder and Bushman,
2000; Skalka and Katz, 2005). BMP2K is a putative serine/
threonine protein kinase localized to the cell nucleus and ap-
pears, like SERPINB6 and NEIL3, to play a role in HIV replication
at a step up to or at the level of integration. CD97 is a GPCRCell Host &primarily expressed in T lymphocytes that appears to play a post-
integration role in HIV infection. The potential for all of these gene
products to be inhibited by a small molecule coupledwith the fact
that knockout mice, when available, are viable and fertile, makes
these potential targets for the development of treatments for HIV
disease (Hopkins and Groom, 2002; Scarff et al., 2004; Wang
et al., 2007; Torisu et al., 2005).
RNAi has become a powerful tool that allows systematic
interrogation of thousands of human genes with respect to a
particular function or disease phenotype. However, owing to the
potential for siRNA transfection to result in ‘‘off-target effects,’’ or
the silencing of untargeted mRNAs, along with variability both in
siRNA efficacy and protein half-lives that will ultimately result in
different levels of protein knockdown, any genome-scale siRNA
screen is likely to include false positive and false negative data.
Thus, RNAi-based screens only provide a starting point in the
identification of potential genetic elements in a given biological
process, and additional confirmatory studies are required.
EXPERIMENTAL PROCEDURES
Cells and Vrus
HeLa P4/R5 cells are a subline of cells that are highly permissive for HIV
infection (Clavel andCharneau, 1994). Cells weremaintained in DMEMsupple-
mented with 10% FBS and 1 mg/ml puromycin. HIV-1 HXB2 stock was
purchased from Advanced Biotechnologies (Columbia, MD).
siRNA Data Analysis
High data quality was assured through implementing quality control proce-
dures described (Zhang et al., 2006, 2007; Zhang, 2007a, 2007b). It is impor-
tant that hit selection methods are robust to outliers in genome-scale RNAi
screens. Therefore, we used the methods described to identify outliers. These
outliers were excluded in the calculation of means and standard deviations.
Based on these robust means and standard deviations, we calculated SSMD
for all siRNAs including outliers and then selected hits using the SSMD-based
methods described (Zhang et al., 2006, 2007; Zhang, 2007a, 2007b).
Quantitative PCR
Total cellular RNA was purified by RNeasy Plus RNA isolation kit fromQIAGEN
(Valencia, CA). Taqman assay kits were ordered from Applied Biosystems
(Foster City, CA). The relative amount of target gene mRNA was normalized
to cyclophilin mRNA.
Plasmids and cDNA Rescue Experiment
The coding sequence for the indicated genes was confirmed in a pEntry vector
and then recombined into pcDNA 3.1 using LR recombinase (Invitrogen).
siRNA and the indicated expression plasmid was contransfected into HeLa
P4/R5 cells using Lipofectamine 2000 (Invitrogen). After 36 hr, cells were
infected with HIV HXB2. HIV infection was quantified by measuring b-gal
activity at 48 hr after infection.
HIV-Tat Transcriptional Activation Assay
HeLa P4/R5 cells were transfected with siRNA pools using Oligofectamine
(Invitrogen). Two days following siRNA transfection, the cells were transfected
with pUCd5-Tat, an expression vector for HIV-Tat (Mancebo et al., 1997). One
day following transfection with pUCd5-Tat, Tat activation of expression of the
b-gal reporter gene was monitored using Gal-Screen (Applied Biosystems).(B) siRNAs against BMP2K, NEIL3, and Serpin B6 decreased viral reverse transcription product level. HeLa P4/R5 cells were transfected with the indicated
siRNAs for 48 hr, then infected with HIV. DNA was prepared after an additional 24 hr, and viral DNA level was measured by Q-PCR as in Butler et al. (2001)
and expressed as the percentage of RT product relative to the luciferase negative control. Standard deviation is shown (N = 3).
(C) siRNAs against BMP2K, NEIL3, and Serpin B6 decreased viral integration. P4/R5 cells were transfected with the indicated siRNAs for 48 hr, then infected with
HIV. DNA was prepared after an additional 48 hr, and Alu-LTR levels were quantified by Q-PCR as in Butler et al. (2001) and expressed as the percentage of
integration product relative to the luciferase negative control. Standard deviation is shown (N = 3).Microbe 4, 495–504, November 13, 2008 ª2008 Elsevier Inc. 503
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HeLa P4/R5 cells were transfected with siRNA as described above. Cells were
infected with HIV HXB2 24 hr after transfection, and DNA was extracted with
DNeasy kit from QIAGEN at both 48 hr postinfection and 72 hr postinfection.
Five NCR and Alu-LTR were analyzed as described (Butler et al., 2001).
SUPPLEMENTAL DATA
Supplemental Data include three figures, five tables, Supplemental Experi-
mental Procedures, Supplemental Acknowledgments, and Supplemental Ref-
erences and can be found online at http://www.cell.com/cellhostandmicrobe/
supplemental/S1931-3128(08)00330-2.
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